Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Bladder Cancer, June 2021

Free Subscription


Abstracts

Retrieve all available abstracts of the following 171 articles:
HTML format


 

Single Articles

  1. VELMAHOS CS, Badgeley M, Lo YC
    Using deep learning to identify bladder cancers with FGFR-activating mutations from histology images.
    Cancer Med. 2021 Jun 10. doi: 10.1002/cam4.4044.
    PubMed    
    Abstract available

  2. PARK RM, Carreon T, Hanley KW
    Risk assessment for o-toluidine and bladder cancer incidence.
    Am J Ind Med. 2021 Jun 10. doi: 10.1002/ajim.23265.
    PubMed    
    Abstract available

  3. WU H, Jiang W, Ji G, Xu R, et al
    Exploring microRNA target genes and identifying hub genes in bladder cancer based on bioinformatic analysis.
    BMC Urol. 2021;21:90.
    PubMed    
    Abstract available

  4. PEIXOTO A, Ferreira D, Azevedo R, Freitas R, et al
    Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer.
    J Exp Clin Cancer Res. 2021;40:191.
    PubMed    
    Abstract available

  5. MORELLI M, Baboudjian M, Vanacore D, Gondran-Tellier B, et al
    Early PDD Cystoscopy after BCG Induction for High-risk Non-Muscle Invasive Bladder Cancer Significantly Increased the Detection of BCG-refractory Tumors.
    J Endourol. 2021 Jun 9. doi: 10.1089/end.2021.0313.
    PubMed    
    Abstract available

  6. SASAKI Y, Kadoriku F, Fukatani Y, Yamamoto H, et al
    [A Case of Robot-Assisted Radical Cystoprostatectomy for Locally Advanced Prostate Cancer with Bladder Infiltration].
    Hinyokika Kiyo. 2021;67:163-166.
    PubMed    
    Abstract available

  7. ZUO Y, Xu X, Chen M, Qi L, et al
    The oncogenic role of the cerebral endothelial cell adhesion molecule (CERCAM) in bladder cancer cells in vitro and in vivo.
    Cancer Med. 2021 Jun 8. doi: 10.1002/cam4.3955.
    PubMed    
    Abstract available

  8. ZHOU L, Xu B, Liu Y, Wang Z, et al
    Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer.
    Oncoimmunology. 2021;10:1915574.
    PubMed    
    Abstract available

  9. HAN X, Liu J, Liu Y, Mou L, et al
    LINC-PINT Inhibited Malignant Progression of Bladder Cancer by Targeting miR-155-5p.
    Cancer Manag Res. 2021;13:4393-4401.
    PubMed    
    Abstract available

  10. BRISUDA A, Ho JCS, Kandiyal PS, Ng JT, et al
    Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex.
    Nat Commun. 2021;12:3427.
    PubMed    
    Abstract available

  11. ISLAM MK, Syed P, Dhondt B, Gidwani K, et al
    Detection of Bladder Cancer with Aberrantly Fucosylated ITGA3.
    Anal Biochem. 2021 Jun 5:114283. doi: 10.1016/j.ab.2021.114283.
    PubMed    
    Abstract available

  12. PHAM QT, Taniyama D, Akabane S, Harada K, et al
    TDO2 overexpression correlates with poor prognosis, cancer stemness, and resistance to cetuximab in bladder cancer.
    Cancer Rep (Hoboken). 2021 Jun 7:e1417. doi: 10.1002/cnr2.1417.
    PubMed    
    Abstract available

  13. KOZIKOWSKI M, Suarez-Ibarrola R, Osiecki R, Bilski K, et al
    Role of Radiomics in the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Eur Urol Focus. 2021 Jun 4. pii: S2405-4569(21)00157.
    PubMed    
    Abstract available

  14. NOONE AM, Lam CJK, Smith AB, Nielsen ME, et al
    Machine Learning Methods to Identify Missed Cases of Bladder Cancer in Population-Based Registries.
    JCO Clin Cancer Inform. 2021;5:641-653.
    PubMed    
    Abstract available

  15. PHAM STD, Lee A, Struminger JS, Belkoff KM, et al
    Mycotic infrarenal aortic aneurysm due to mycobacterium after intravesical treatment for bladder cancer.
    J Vasc Surg Cases Innov Tech. 2021;7:354-356.
    PubMed    
    Abstract available

  16. LIU J, Ma H, Meng L, Liu X, et al
    Construction and External Validation of a Ferroptosis-Related Gene Signature of Predictive Value for the Overall Survival in Bladder Cancer.
    Front Mol Biosci. 2021;8:675651.
    PubMed    
    Abstract available

  17. EPAILLARD N, Parent P, Loriot Y, Lavaud P, et al
    Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study.
    Front Oncol. 2021;11:671969.
    PubMed    
    Abstract available

  18. LI Y, Sun L, Guo X, Mo N, et al
    Frontiers in Bladder Cancer Genomic Research.
    Front Oncol. 2021;11:670729.
    PubMed    
    Abstract available

  19. GUPTA S, Singh B, Bhatt H, Singh S, et al
    A Case of Systemic Toxicity Related to Intravesical Bacillus Calmette-Guerin for the Treatment of Bladder Cancer.
    Cureus. 2021;13:e15321.
    PubMed    
    Abstract available

  20. SHIH KW, Chen WC, Chang CH, Tai TE, et al
    Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions.
    Aging Dis. 2021;12:868-885.
    PubMed    
    Abstract available

  21. LIU Z, Liu X, Cai R, Liu M, et al
    Identification of a tumor microenvironment-associated prognostic gene signature in bladder cancer by integrated bioinformatic analysis.
    Int J Clin Exp Pathol. 2021;14:551-566.
    PubMed    
    Abstract available

  22. JOBCZYK M, Stawiski K, Kaszkowiak M, Rajwa P, et al
    Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Non-muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2021 Jun 3. pii: S2588-9311(21)00112.
    PubMed    
    Abstract available

  23. STEINBERG RL, Packiam VT, Thomas LJ, Brooks N, et al
    Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.
    Urol Oncol. 2021 Jun 3. pii: S1078-1439(21)00134.
    PubMed    
    Abstract available

  24. LIN JY, Juo BR, Yeh YH, Fu SH, et al
    Putative markers for the detection of early-stage bladder cancer selected by urine metabolomics.
    BMC Bioinformatics. 2021;22:305.
    PubMed    
    Abstract available

  25. LAI WH, Fang CY, Chou MC, Lin MC, et al
    Peptide-guided JC polyomavirus-like particles specifically target bladder cancer cells for gene therapy.
    Sci Rep. 2021;11:11889.
    PubMed    
    Abstract available

  26. KIM HS, Seo HK
    Emerging treatments for bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer.
    Investig Clin Urol. 2021 May 27. pii: 62.e49. doi: 10.4111/icu.20200602.
    PubMed    
    Abstract available

  27. EL-SHAL AS, Shalaby SM, Abouhashem SE, Elbary EHA, et al
    Urinary exosomal microRNA-96-5p and microRNA-183-5p expression as potential biomarkers of bladder cancer.
    Mol Biol Rep. 2021 Jun 4. pii: 10.1007/s11033-021-06451.
    PubMed    
    Abstract available

  28. STERN R, Roscoe C, Misch EA
    Mycobacterium bovis BCG osteoarticular infection complicating immune therapy for bladder cancer: a case report.
    J Bone Jt Infect. 2021;6:107-110.
    PubMed    
    Abstract available

  29. SHANTHARAM G, Amin A, Pereira J, Kott O, et al
    Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guerin failure.
    Curr Urol. 2021;15:33-38.
    PubMed    
    Abstract available

  30. SCIARRA A, Di Lascio G, Del Giudice F, Leoncini PP, et al
    Comparison of the clinical usefulness of different urinary tests for the initial detection of bladder cancer: a systematic review.
    Curr Urol. 2021;15:22-32.
    PubMed    
    Abstract available

  31. MATSUOKA Y, Taoka R, Kohashiguchi K, Tohi Y, et al
    Efficacy and toxicity of intravesical Bacillus Calmette-Guerin therapy in elderly patients with non-muscle-invasive bladder cancer.
    Curr Urol. 2021;15:16-21.
    PubMed    
    Abstract available

  32. MOHAMED DO, Sayed MM, Abdelkawi IF, Elshoieby MH, et al
    Bladder preservation versus radical cystectomy in transitional cell carcinoma and squamous cell carcinoma muscle invasive bladder cancer.
    Curr Urol. 2021;15:11-15.
    PubMed    
    Abstract available

  33. EL KHATIB S
    In vivo photobleaching kinetics and epithelial biodistribution of hexylaminolevulinate-induced protoporphyrin IX in rat bladder cancer.
    Curr Urol. 2021;15:2-10.
    PubMed    
    Abstract available

  34. QI Y, Tang D
    Commentary: Bladder cancer.
    Curr Urol. 2021;15:1.
    PubMed    


  35. HEKTOEN HH, Robsahm TE, Stenehjem JS, Axcrona K, et al
    Vitamin D and Vitamin D-binding protein and risk of bladder cancer: A nested case-control study in the Norwegian Janus Serum Bank Cohort.
    Cancer Med. 2021 Jun 3. doi: 10.1002/cam4.3960.
    PubMed    
    Abstract available

  36. AIZCORBE GOMEZ M, Gutierrez Zurimendi G, Arruza Echevarria A
    [Clinicopathologic analysis of 5 cases of urachal adenocarcinoma.]
    Arch Esp Urol. 2021;74:535-540.
    PubMed    
    Abstract available

  37. SANCHEZ VERDES P, Fernandez-Pello S, Gonzalez Rodriguez I, Salgado Plonski JJ, et al
    [Gross hematuria and usefulness of urinary cytology: Experience at hematuria one stop clinic.]
    Arch Esp Urol. 2021;74:470-476.
    PubMed    
    Abstract available

  38. CAI Q, Wen Z, Huang Y, Li M, et al
    Investigation of Synthetic Magnetic Resonance Imaging Applied in the Evaluation of the Tumor Grade of Bladder Cancer.
    J Magn Reson Imaging. 2021 Jun 3. doi: 10.1002/jmri.27770.
    PubMed    
    Abstract available

  39. BASU M, Chatterjee A, Chakraborty B, Chatterjee E, et al
    High nuclear expression of HIF1alpha, synergizing with inactivation of LIMD1 and VHL, portray worst prognosis among the bladder cancer patients: association with arsenic prevalence.
    J Cancer Res Clin Oncol. 2021 Jun 2. pii: 10.1007/s00432-021-03661.
    PubMed    
    Abstract available

  40. SEGATTO NV, Bender CB, Seixas FK, Schachtschneider K, et al
    Perspective: Humanized Pig Models of Bladder Cancer.
    Front Mol Biosci. 2021;8:681044.
    PubMed    
    Abstract available

  41. JIANG LR, Zhang N, Chen ST, He J, et al
    PD-1-Positive Tumor-Associated Macrophages Define Poor Clinical Outcomes in Patients With Muscle Invasive Bladder Cancer Through Potential CD68/PD-1 Complex Interactions.
    Front Oncol. 2021;11:679928.
    PubMed    
    Abstract available

  42. XU A, Yang GG, Zhang Y, Zhao ST, et al
    Heptaphylline suppresses the proliferation and migration of human bladder cancer cells via induction of intrinsic apoptosis, autophagy and inhibition of beta-catenin signalling pathway.
    J BUON. 2021;26:646.
    PubMed    
    Abstract available

  43. SERRETTA V, Berardinis E, Simonato A, Guarneri A, et al
    A prospective observational study on oral administration of Ellagic Acid and Annona Muricata in patients affected by non-muscle invasive bladder cancer not undergoing maintenance after 6-week intravesical prophylaxis.
    Urologia. 2021 Jun 2:3915603211022285. doi: 10.1177/03915603211022285.
    PubMed    
    Abstract available

  44. ULAMEC M, Murgic J, Novosel L, Tomic M, et al
    New Insights into the Diagnosis, Molecular Taxonomy, and Treatment of Bladder Cancer.
    Acta Med Acad. 2021;50:143-156.
    PubMed    
    Abstract available

  45. HEMMINKI K, Forsti A, Hemminki A, Ljungberg B, et al
    Incidence trends in lung and bladder cancers in the Nordic Countries before and after the smoking epidemic.
    Eur J Cancer Prev. 2021 Jun 1. pii: 00008469-900000000-99039.
    PubMed    
    Abstract available

  46. ZHENG XN, Qiu S, Tang LS, Ai JZ, et al
    Tumor microenvironment-based drug discovery: a novel insight into bladder cancer immunotherapy.
    Chin Med J (Engl). 2021 Jun 2. pii: 00029330-900000000-98594.
    PubMed    


  47. MIYAKE M, Nishimura N, Iida K, Fujii T, et al
    Intravesical Bacillus Calmette-Guerin Treatment for T1 High-Grade Non-Muscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  48. JUTTE H, Reike M, Wirtz RM, Kriegmair M, et al
    KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    J Pers Med. 2021;11.
    PubMed    
    Abstract available

  49. LORAS A, Segovia C, Ruiz-Cerda JL
    Epigenomic and Metabolomic Integration Reveals Dynamic Metabolic Regulation in Bladder Cancer.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  50. SCHNEIDER L, Liu J, Zhang C, Azoitei A, et al
    The Role of Interleukin-1-Receptor-Antagonist in Bladder Cancer Cell Migration and Invasion.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  51. ZHAO Z, Wang Y, Zhang JJ, Huang XY, et al
    Fascin Inhibitors Decrease Cell Migration and Adhesion While Increase Overall Survival of Mice Bearing Bladder Cancers.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  52. NIK AB KADIR MN, Mohd Hairon S, Yaacob NM, Ab Manan A, et al
    Survival and Characteristics of Bladder Cancer: Analysis of the Malaysian National Cancer Registry.
    Int J Environ Res Public Health. 2021;18.
    PubMed    
    Abstract available

  53. PONES M, D'Andrea D, Mori K, Abufraj M, et al
    Differential Prognosis and Response of Denovo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  54. IDE H, Miyamoto H
    Sex Hormone Receptor Signaling in Bladder Cancer: A Potential Target for Enhancing the Efficacy of Conventional Non-Surgical Therapy.
    Cells. 2021;10.
    PubMed    
    Abstract available

  55. KLINGER D, Hill BL, Barda N, Halperin E, et al
    Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer's Disease and Parkinson's Disease.
    Vaccines (Basel). 2021;9.
    PubMed    
    Abstract available

  56. CUCCURULLO V, Di Stasio GD, Manti F, Arcuri P, et al
    The Role of Molecular Imaging in a Muscle-Invasive Bladder Cancer Patient: A Narrative Review in the Era of Multimodality Treatment.
    Diagnostics (Basel). 2021;11.
    PubMed    
    Abstract available

  57. CANNON-ALBRIGHT LA, Teerlink CC, Stevens J, Huang FW, et al
    A Rare Variant in ERF (rs144812092) Predisposes to Prostate and Bladder Cancers in an Extended Pedigree.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  58. BARANI M, Hosseinikhah SM, Rahdar A, Farhoudi L, et al
    Nanotechnology in Bladder Cancer: Diagnosis and Treatment.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  59. HOFFMAN-CENSITS J, Kanesvaran R, Bangs R, Fashoyin-Aje L, et al
    Breaking Barriers: Addressing Issues of Inequality in Trial Enrollment and Clinical Outcomes for Patients With Kidney and Bladder Cancer.
    Am Soc Clin Oncol Educ Book. 2021;41:e174-e181.
    PubMed    
    Abstract available

  60. HUANG J, Zhao L, Wang K, Sun J, et al
    Controlling Nutritional Status Score Evaluates Prognosis in Patients With Non-Muscle Invasive Bladder Cancer.
    Cancer Control. 2021;28:10732748211021078.
    PubMed    
    Abstract available

  61. CONTIERI R, Paciotti M, Lughezzani G, Buffi NM, et al
    Long-term Follow-up and Factors Associated with Active Surveillance Failure for Patients with Non-muscle-invasive Bladder Cancer: The Bladder Cancer Italian Active Surveillance (BIAS) Experience.
    Eur Urol Oncol. 2021 May 28. pii: S2588-9311(21)00108.
    PubMed    
    Abstract available

  62. MOUSSA M, Chakra MA, Saad W, Dellis A, et al
    The role of 18F-FDG PET/CT scan compared to CT-scan alone for lymph node staging before radical cystectomy in patients with bladder cancer.
    Urol Oncol. 2021 May 29. pii: S1078-1439(21)00183.
    PubMed    
    Abstract available

  63. ZHAO X, Li G, Chong T, Xue L, et al
    TMEM88 exhibits an antiproliferative and anti-invasive effect in bladder cancer by downregulating Wnt/beta-catenin signaling.
    J Biochem Mol Toxicol. 2021 May 31:e22835. doi: 10.1002/jbt.22835.
    PubMed    
    Abstract available

  64. BEINFELD M, Atlas SJ, Touchette D, McKenna A, et al
    The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer.
    J Manag Care Spec Pharm. 2021;27:797-804.
    PubMed    
    Abstract available

  65. YE W, Chen L, Feng C, Liang T, et al
    CircMYLK promotes the growth, migration, invasion, and survival of bladder cancer cells by upregulating CCND3 level via competitively binding to miR-34a.
    Drug Dev Res. 2021 May 30. doi: 10.1002/ddr.21835.
    PubMed    
    Abstract available

  66. CHAI CA, Yeoh WS, Rajandram R, Aung KP, et al
    Comparing CxBladder to Urine Cytology as Adjunct to Cystoscopy in Surveillance of Non-muscle Invasive Bladder Cancer-A Pilot Study.
    Front Surg. 2021;8:659292.
    PubMed    
    Abstract available

  67. GUO C, Li X, Xie J, Liu D, et al
    Long Noncoding RNA SNHG1 Activates Autophagy and Promotes Cell Invasion in Bladder Cancer.
    Front Oncol. 2021;11:660551.
    PubMed    
    Abstract available

  68. ZHENG Z, Xu F, Gu Z, Yan Y, et al
    Combining Multiparametric MRI Radiomics Signature With the Vesical Imaging-Reporting and Data System (VI-RADS) Score to Preoperatively Differentiate Muscle Invasion of Bladder Cancer.
    Front Oncol. 2021;11:619893.
    PubMed    
    Abstract available

  69. CHAO Y, Ou Q, Shang J
    Expression and prognostic value of SULT1A2 in bladder cancer.
    Exp Ther Med. 2021;22:779.
    PubMed    
    Abstract available

  70. BRATU O, Marcu D, Anghel R, Spinu D, et al
    Tumoral markers in bladder cancer (Review).
    Exp Ther Med. 2021;22:773.
    PubMed    
    Abstract available

  71. MATULEWICZ RS, Ravvaz K, Weissert JA, Porten S, et al
    Association of smoking status and recurrence of non-muscle invasive bladder cancer among patients managed with blue light cystoscopy.
    Urol Oncol. 2021 May 27. pii: S1078-1439(21)00185.
    PubMed    
    Abstract available

  72. DU Y, Jiang X, Wang B, Cao J, et al
    The cancer-associated fibroblasts related gene CALD1 is a prognostic biomarker and correlated with immune infiltration in bladder cancer.
    Cancer Cell Int. 2021;21:283.
    PubMed    
    Abstract available

  73. BALAR AV, Kamat AM, Kulkarni GS, Uchio EM, et al
    Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
    Lancet Oncol. 2021 May 26. pii: S1470-2045(21)00147.
    PubMed    
    Abstract available

  74. ALKASSIS M, Abi Tayeh G, Khalil N, Mansour R, et al
    The Safety and Efficacy of Bacillus Calmette-Guerin Intravesical Therapy in Kidney Transplant Recipients with Superficial Bladder Cancer.
    Clin Transplant. 2021 May 29:e14377. doi: 10.1111/ctr.14377.
    PubMed    
    Abstract available

  75. CLAPS F, Rai S, Mir MC, van Rhijn BWG, et al
    Prognostic value of preoperative albumin-to-fibrinogen ratio (AFR) in patients with bladder cancer treated with radical cystectomy.
    Urol Oncol. 2021 May 25. pii: S1078-1439(21)00184.
    PubMed    
    Abstract available

  76. GRIVAS P, Agarwal N, Pal S, Kalebasty AR, et al
    Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.
    Cancer Treat Rev. 2021;97:102187.
    PubMed    
    Abstract available

  77. LIM JX, Chan SKS, Hwang PYK
    Trans-sulcal parafascicular approach to subcortical lesions.
    J Clin Neurosci. 2021;86:45-49.
    PubMed    
    Abstract available

  78. ROSENBERG JE
    New treatments for patients with progressive metastatic urothelial carcinoma.
    Clin Adv Hematol Oncol. 2021;19:180-183.
    PubMed    


  79. ANNO T, Kikuchi E, Shigeta K, Ogihara K, et al
    Site-specific differences in survival among upper and lower tract urothelial carcinoma patients treated with radical surgery.
    Jpn J Clin Oncol. 2021;51:984-991.
    PubMed    
    Abstract available

  80. WANG L, Tao H, Li Z, Lei Y, et al
    Preparation of Composite Cypate Nanoparticles and Its Application in the Treatment of Pediatric Bladder Tumors.
    J Nanosci Nanotechnol. 2021;21:868-877.
    PubMed    
    Abstract available

  81. APPLEMAN LJ
    Multifactorial, Biomarker-Based Predictive Models for Immunotherapy Response Enter the Arena.
    J Natl Cancer Inst. 2021;113:7-8.
    PubMed    


  82. DENG G, Wang R, Sun Y, Huang CP, et al
    Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARgamma/MMP-9 signals.
    Cell Death Differ. 2021 Jun 14. pii: 10.1038/s41418-021-00743.
    PubMed    
    Abstract available

  83. LAUKHTINA E, Rajwa P, Mori K, Moschini M, et al
    Accuracy of Frozen Section Analysis of Urethral and Ureteral Margins During Radical Cystectomy for Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis.
    Eur Urol Focus. 2021 Jun 11. pii: S2405-4569(21)00162.
    PubMed    
    Abstract available

  84. HAN MA, Maisch P, Jung JH, Hwang JE, et al
    Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Cochrane Database Syst Rev. 2021;6:CD009294.
    PubMed    
    Abstract available

  85. THOMSEN JA, Nielsen Dominiak H, Lindgren MS, Jensen JB, et al
    Adverse events of hyperthermic intravesical chemotherapy for non-muscle invasive bladder cancer patients.
    Scand J Urol. 2021 Jun 14:1-6. doi: 10.1080/21681805.2021.1938664.
    PubMed    
    Abstract available

  86. ASATANI S, Kanda T, Honda M, Ishii T, et al
    Occurrence of hepatitis in an elderly woman during the treatment of pembrolizumab for right advanced renal pelvis, ureteral cancer, and bladder cancer.
    JGH Open. 2021;5:722-724.
    PubMed    
    Abstract available

  87. GENG Z, Geng Q
    Risk of Urinary Bladder Cancer in Patients With Inflammatory Bowel Diseases: A Meta-Analysis.
    Front Surg. 2021;8:636791.
    PubMed    
    Abstract available

  88. ZANG J, Ye K, Fei Y, Zhang R, et al
    Immunotherapy in the Treatment of Urothelial Bladder Cancer: Insights From Single-Cell Analysis.
    Front Oncol. 2021;11:696716.
    PubMed    
    Abstract available

  89. BOGEN JP, Grzeschik J, Jakobsen J, Bahre A, et al
    Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics.
    Front Oncol. 2021;11:672262.
    PubMed    
    Abstract available

  90. XIAO J, Gong L, Xiao M, He D, et al
    LINC00467 Promotes Tumor Progression via Regulation of the NF-kb Signal Axis in Bladder Cancer.
    Front Oncol. 2021;11:652206.
    PubMed    
    Abstract available

  91. ZHOU Z, Cui Y, Huang S, Chen Z, et al
    The Efficacy of Intra-Arterial Plus Intravesical Chemotherapy Versus Intravesical Chemotherapy Alone After Bladder-Sparing Surgery in High-Risk Bladder Cancer: A Systematic Review and Meta-Analysis of Comparative Study.
    Front Oncol. 2021;11:651657.
    PubMed    
    Abstract available

  92. DONG D, Yao Y, Song J, Sun L, et al
    Cancer-Associated Fibroblasts Regulate Bladder Cancer Invasion and Metabolic Phenotypes through Autophagy.
    Dis Markers. 2021;2021:6645220.
    PubMed    
    Abstract available

  93. ZHANG F, Wang X, Bai Y, Hu H, et al
    Development and Validation of a Hypoxia-Related Signature for Predicting Survival Outcomes in Patients With Bladder Cancer.
    Front Genet. 2021;12:670384.
    PubMed    
    Abstract available

  94. KOCAK SY, Kudu A, Apaydin S
    Bacillus Calmette-Guerin-induced perinuclear antineutrophil cytoplasmic antibodies associated vasculitis in bladder cancer.
    J Cancer Res Ther. 2021;17:609-612.
    PubMed    
    Abstract available

  95. CULPAN M, Turan T, Ozkanli SS, Zenginkinet T, et al
    Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer.
    J Cancer Res Ther. 2021;17:434-442.
    PubMed    
    Abstract available

  96. KIM DK, Kim YH, Lee HY, Lee S, et al
    Diagnostic accuracy of Raman spectroscopy for the diagnosis of bladder cancer: A systematic review and meta-analysis.
    J Cancer Res Ther. 2021;17:426-433.
    PubMed    
    Abstract available

  97. KAMAKURA M, Okazaki A, Ito K, Kin F, et al
    Concomitant Pulmonary and Cerebral Tumor Embolism and Intracardiac Metastasis from Bladder Cancer.
    Intern Med. 2021 Jun 12. doi: 10.2169/internalmedicine.6765.
    PubMed    
    Abstract available

  98. KARKIN K, Izol V, Kaplan M, Deger M, et al
    Demonstration of Advanced Glycation End product (AGE) Expression in Bladder Cancer Tissue in Type 2 Diabetic and Non-diabetic Patients and the Relationship between AGE Accumulation and Endoplasmic Reticulum Stress (ERS) with Bladder Cancer.
    Int J Clin Pract. 2021 Jun 13:e14526. doi: 10.1111/ijcp.14526.
    PubMed    
    Abstract available

  99. KIMURA K, Yoshida S, Tsuchiya J, Yamada I, et al
    Usefulness of texture features of apparent diffusion coefficient maps in predicting chemoradiotherapy response in muscle-invasive bladder cancer.
    Eur Radiol. 2021 Jun 13. pii: 10.1007/s00330-021-08110.
    PubMed    
    Abstract available

  100. SEYYEDSALEHI MS, Mohebbi E, Sasanfar B, Toorang F, et al
    Dietary N-nitroso compounds intake and bladder cancer risk: A systematic review and meta-analysis.
    Nitric Oxide. 2021;115:1-7.
    PubMed    
    Abstract available

  101. SHI S, Ma T, Xi Y
    Characterization of the immune cell infiltration landscape in bladder cancer to aid immunotherapy.
    Arch Biochem Biophys. 2021;708:108950.
    PubMed    
    Abstract available

  102. BREE KK, Hensley PJ, Brooks N, Matulay J, et al
    Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center.
    World J Urol. 2021 Jun 12. pii: 10.1007/s00345-021-03755.
    PubMed    
    Abstract available

  103. CULPAN M, Keser F, Acar HC, Otunctemur A, et al
    Impact of delay in cystoscopic surveillance on recurrence and progression rates in non-muscle invasive bladder cancer patients during COVID-19 pandemic.
    Int J Clin Pract. 2021 Jun 12:e14490. doi: 10.1111/ijcp.14490.
    PubMed    
    Abstract available

  104. KIM JI, Zhu D, Barry E, Kovac E, et al
    Intravesical Bacillus Calmette-Guerin Treatment Is Inversely Associated With the Risk of Developing Alzheimer Disease or Other Dementia Among Patients With Non-muscle-invasive Bladder Cancer.
    Clin Genitourin Cancer. 2021 May 17. pii: S1558-7673(21)00096.
    PubMed    
    Abstract available

  105. LIN G, Zhang J, Wu Y, Zhu S, et al
    Signatures and Prognostic Values of N6-methyladenosine (m6A) - related Immune Genes in Bladder Cancer.
    Bioengineered. 2021;12:2649-2663.
    PubMed    
    Abstract available

  106. REXER H, Kubler H, Retz M

    Aktuelle Urol. 2021;52:220-221.
    PubMed    


  107. LAMPEL A, Schultz-Lampel D
    [Urinary diversion after uro-oncologic interventions in women: the right procedure for the right patient].
    Aktuelle Urol. 2021;52:268-275.
    PubMed    
    Abstract available

  108. GRUBA N, Stachurski L, Lesner A
    Elastolytic activity is associated with inflammation in bladder cancer.
    J Biochem. 2021 Jun 24. pii: 6308946. doi: 10.1093.
    PubMed    
    Abstract available

  109. CAO J, Li J, Yang X, Li P, et al
    Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer.
    Cancer Med. 2021 Jun 24. doi: 10.1002/cam4.4071.
    PubMed    
    Abstract available

  110. KIM HJ, Chun J, Kim TH, Yang G, et al
    Patterns of Locoregional Recurrence after Radical Cystectomy for Stage T3-4 Bladder Cancer: A Radiation Oncologist's Point of View.
    Yonsei Med J. 2021;62:569-576.
    PubMed    
    Abstract available

  111. MONTAZERI K, Dranitsaris G, Thomas JD, Curran C, et al
    An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer.
    Urol Oncol. 2021 Jun 20. pii: S1078-1439(21)00190.
    PubMed    
    Abstract available

  112. KUKREJA JB, Schroeck FR, Lotan Y, Gore JL, et al
    Discomfort and relieving factors among patients with bladder cancer undergoing office-based cystoscopy.
    Urol Oncol. 2021 Jun 20. pii: S1078-1439(21)00215.
    PubMed    
    Abstract available

  113. PEKALA KR, Yabes JG, Bandari J, Yu M, et al
    The centralization of bladder cancer care and its implications for patient travel distance.
    Urol Oncol. 2021 Jun 20. pii: S1078-1439(21)00187.
    PubMed    
    Abstract available

  114. LIU J, Zhang Y, Zeng H, Wang L, et al
    Fe-doped chrysotile nanotubes containing siRNAs to silence SPAG5 to treat bladder cancer.
    J Nanobiotechnology. 2021;19:189.
    PubMed    
    Abstract available

  115. PLYUSHCHENKO IV, Fedorova ES, Potoldykova NV, Polyakovskiy KA, et al
    Omics Untargeted Key Script: R-Based Software Toolbox for Untargeted Metabolomics with Bladder Cancer Biomarkers Discovery Case Study.
    J Proteome Res. 2021 Jun 23. doi: 10.1021/acs.jproteome.1c00392.
    PubMed    
    Abstract available

  116. GROBET-JEANDIN E, Pinar U, Loriot Y, Roupret M, et al
    ["Treatment of bladder cancer with immune checkpoints inhibitors"].
    Rev Prat. 2021;71:391-395.
    PubMed    
    Abstract available

  117. FU Y, Sun S, Bi J, Kong C, et al
    Construction and analysis of a ceRNA network and patterns of immune infiltration in bladder cancer.
    Transl Androl Urol. 2021;10:1939-1955.
    PubMed    
    Abstract available

  118. WILLIAMS SB, Gavaghan MB, Fernandez A, Daneshmand S, et al
    Macro and microeconomics of blue light cystoscopy with CYSVIEW(R) in non-muscle invasive bladder cancer.
    Urol Oncol. 2021 Jun 20. pii: S1078-1439(21)00231.
    PubMed    
    Abstract available

  119. DE JONG JJ, Narayan VM, Cronican AA, Gupta S, et al
    Gene Expression Profiling of Muscle-Invasive Bladder Cancer With Secondary Variant Histology.
    Am J Clin Pathol. 2021 Jun 22. pii: 6307930. doi: 10.1093.
    PubMed    
    Abstract available

  120. PLASEK J, Weissert J, Downs T, Richards K, et al
    Clinicopathological Criteria Predictive of Recurrence Following Bacillus Calmette-Guerin Therapy Initiation in Non-Muscle-Invasive Bladder Cancer: Retrospective Cohort Study.
    JMIR Cancer. 2021;7:e25800.
    PubMed    
    Abstract available

  121. KORKES F, Spiess PE, Garcia-Perdomo HA, Necchi A, et al
    Challenging dilemmas of low grade, non-invasive bladder cancer: a narrative review.
    Int Braz J Urol. 2021;47.
    PubMed    
    Abstract available

  122. IGEL DA, Lee EK
    The role of technology in the perioperative management of bladder cancer patients.
    Urol Oncol. 2021 Jun 18. pii: S1078-1439(21)00179.
    PubMed    
    Abstract available

  123. ZHANG J, Zhou Q, Xie K, Cheng L, et al
    Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer.
    J Exp Clin Cancer Res. 2021;40:203.
    PubMed    
    Abstract available

  124. KHALIFA MK, Bakr NM, Ramadan A, Abd Elwahab KM, et al
    Implications of targeted next-generation sequencing for bladder cancer: report of four cases.
    J Genet Eng Biotechnol. 2021;19:91.
    PubMed    
    Abstract available

  125. YE R, Zeng H, Liu Z, Jin K, et al
    Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis.
    Cancer Immunol Immunother. 2021 Jun 21. pii: 10.1007/s00262-021-02987.
    PubMed    
    Abstract available

  126. DU Y, Miao W, Jiang X, Cao J, et al
    The Epithelial to Mesenchymal Transition Related Gene Calumenin Is an Adverse Prognostic Factor of Bladder Cancer Correlated With Tumor Microenvironment Remodeling, Gene Mutation, and Ferroptosis.
    Front Oncol. 2021;11:683951.
    PubMed    
    Abstract available

  127. LUO C, Ye W, Hu J, Othmane B, et al
    A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer.
    Front Oncol. 2021;11:660273.
    PubMed    
    Abstract available

  128. MATSUI Y
    A case of inflammatory myofibroblastic tumor of the urinary bladder with emergency clinical symptoms similar to bladder cancer.
    Urol Case Rep. 2021;38:101740.
    PubMed    
    Abstract available

  129. ZHANG P, Yang Q
    Overexpression of SHMT2 Predicts a Poor Prognosis and Promotes Tumor Cell Growth in Bladder Cancer.
    Front Genet. 2021;12:682856.
    PubMed    
    Abstract available

  130. ZHOU Q, Qian Z, Ding W, Jiang G, et al
    Chronic psychological stress attenuates the efficacy of anti-PD-L1 immunotherapy for bladder cancer in immunocompetent mice.
    Cancer Invest. 2021 Jun 19:1-28. doi: 10.1080/07357907.2021.1943746.
    PubMed    
    Abstract available

  131. GIANNARINI G, Agarwal N, Apolo AB, Briganti A, et al
    Urologists, You'll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non-muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2021 Jun 16. pii: S2588-9311(21)00114.
    PubMed    
    Abstract available

  132. JUE JS, Alameddine M, Gonzale J, Cianci G, et al
    Risk factors, management, and survival of bladder cancer after kidney transplantation.
    Actas Urol Esp (Engl Ed). 2021 Jun 16. pii: S2173-5786(21)00075.
    PubMed    
    Abstract available

  133. BENMERZOUG S, Chevalier MF, Verardo M, Nguyen S, et al
    Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
    Eur Urol Focus. 2021 Jun 16. pii: S2405-4569(21)00163.
    PubMed    
    Abstract available

  134. ZHANG L, Hsieh MC, Allison C, Devane M, et al
    Racial differences in the risk of second primary bladder cancer following radiation therapy among localized prostate cancer patients.
    Cancer Epidemiol. 2021;73:101967.
    PubMed    
    Abstract available

  135. SADETSKY N, Chuo CY, Davidoff AJ
    Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer, bladder cancer, and melanoma: An electronic health record study.
    Pharmacoepidemiol Drug Saf. 2021 Jun 18. doi: 10.1002/pds.5309.
    PubMed    
    Abstract available

  136. CIMADAMORE A, Lopez-Beltran A, Scarpelli M, Cheng L, et al
    Re: Bas W.G. van Rhijn, Anouk E. Hentschel, Johannes Brundl, et al. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology No
    Eur Urol Oncol. 2021 Jun 15. pii: S2588-9311(21)00117.
    PubMed    


  137. OKUBO K, Miyai K, Kato K, Asano T, et al
    Simvastatin-romidepsin combination kills bladder cancer cells synergistically.
    Transl Oncol. 2021;14:101154.
    PubMed    
    Abstract available

  138. KATAYAMA S, Mori K, Pradere B, Laukhtina E, et al
    Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer.
    World J Urol. 2021 Jun 18. pii: 10.1007/s00345-021-03740.
    PubMed    
    Abstract available

  139. IONOV NS, Baryshnikova MA, Bocharov EV, Pogodin PV, et al
    [Possibilities of in silico estimations for the development of pharmaceutical composition phytoladaptogene cytotoxic for bladder cancer cells].
    Biomed Khim. 2021;67:278-288.
    PubMed    
    Abstract available

  140. CHOU KY, Chang AC, Ho CY, Tsai TF, et al
    Thrombospondin-4 promotes bladder cancer cell migration and invasion via MMP2 production.
    J Cell Mol Med. 2021 Jun 17. doi: 10.1111/jcmm.16463.
    PubMed    
    Abstract available

  141. LU JL, Xia QD, Sun Y, Xun Y, et al
    Toll-Like Receptor 4 as a Favorable Prognostic Marker in Bladder Cancer: A Multi-Omics Analysis.
    Front Cell Dev Biol. 2021;9:651560.
    PubMed    
    Abstract available

  142. BOTHIG R, Kowald B, Fiebag K, Balzer O, et al
    Bladder management, severity of injury and period of latency: a descriptive study on 135 patients with spinal cord injury and bladder cancer.
    Spinal Cord. 2021 Jun 17. pii: 10.1038/s41393-021-00651.
    PubMed    
    Abstract available

  143. CIVELEK AC, Niglio SA, Malayeri AA, Lin J, et al
    Clinical value of (18)FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer.
    Urol Oncol. 2021 Jun 14. pii: S1078-1439(21)00181.
    PubMed    
    Abstract available

  144. IQBAL U, Elsayed AS, Jing Z, Stoeckle M, et al
    Upstaging and Survival Outcomes for Non-Muscle Invasive Bladder Cancer After Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.
    J Endourol. 2021 Jun 17. doi: 10.1089/end.2021.0013.
    PubMed    
    Abstract available

  145. NIE Z, Chen M, Wen X, Gao Y, et al
    Endoplasmic Reticulum Stress and Tumor Microenvironment in Bladder Cancer: The Missing Link.
    Front Cell Dev Biol. 2021;9:683940.
    PubMed    
    Abstract available

  146. GAO J, Tian DW, Zhou DS, Wu CL, et al
    Flexible cystoscopy can improve anxiety and subjective feelings of bladder cancer patients during follow-up.
    Wideochir Inne Tech Maloinwazyjne. 2021;16:397-402.
    PubMed    
    Abstract available

  147. TIAN X, Zhu Q, Zhang Z
    Durable Clinical Response to Immune and Targeted Therapies in an Elderly Man with Synchronous Gastric (HER2+) and Bladder Cancers: Case Report and Literature Review.
    Onco Targets Ther. 2021;14:3701-3708.
    PubMed    
    Abstract available

  148. CHOU WH, McGregor B, Schmidt A, Carvalho FLF, et al
    Cyclophosphamide-associated bladder cancers and considerations for survivorship care: A systematic review.
    Urol Oncol. 2021 Jun 13. pii: S1078-1439(21)00223.
    PubMed    
    Abstract available

  149. NITSCHKE K, Worst TS, von Rhade SM, Thaqi B, et al
    High IL-22RA1 gene expression is associated with poor outcome in muscle invasive bladder cancer.
    Urol Oncol. 2021 Jun 13. pii: S1078-1439(21)00216.
    PubMed    
    Abstract available

  150. GRICE P, O'Dowd S, Parkinson R, Bazo A, et al
    Bladder leiomyoma masquerading as a ureterocele.
    BMJ Case Rep. 2021;14.
    PubMed    
    Abstract available

  151. BAJORIN DF, Witjes JA, Gschwend JE, Schenker M, et al
    Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
    N Engl J Med. 2021;384:2102-2114.
    PubMed    
    Abstract available

  152. JERMAN UD, Visnjar T, Bratkovic IH, Resnik N, et al
    Attachment of Cancer Urothelial Cells to the Bladder Epithelium Occurs on Uroplakin-Negative Cells and Is Mediated by Desmosomal and Not by Classical Cadherins.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  153. OZKAPTAN O, Cubuk A, Dincer E, Ipek OM, et al
    Adenocarcinoma in Orthotopic Neobladder 19 Years After Radical Cystoprostatectomy.
    J Coll Physicians Surg Pak. 2021;30:588-590.
    PubMed    
    Abstract available

  154. WITZKE KE, Grosserueschkamp F, Gerwert K, Sitek B, et al
    Application of Label-Free Proteomics for Quantitative Analysis of Urothelial Carcinoma and Cystitis Tissue.
    Methods Mol Biol. 2021;2228:283-292.
    PubMed    
    Abstract available

  155. DENG C, Guo H, Yan D, Liang T, et al
    Pancancer Analysis of Neurovascular-Related NRP Family Genes as Potential Prognostic Biomarkers of Bladder Urothelial Carcinoma.
    Biomed Res Int. 2021;2021:5546612.
    PubMed    
    Abstract available

  156. CHEN CJ, Chou CY, Shu KH, Chen HC, et al
    Discovery of Novel Protein Biomarkers in Urine for Diagnosis of Urothelial Cancer Using iTRAQ Proteomics.
    J Proteome Res. 2021;20:2953-2963.
    PubMed    
    Abstract available

  157. SOBERON JR, Awoniyi CA, Perez MA, Vasilopoulos T, et al
    Obturator Nerve Blockade vs. Neuromuscular Blockade for the Prevention of Adductor Spasm in Patients Undergoing Transurethral Resection of Bladder Tumors: A Randomized Controlled Trial.
    Pain Med. 2021;22:1253-1260.
    PubMed    
    Abstract available

  158. ETANI T, Asaoka M, Kondo S, Wachino C, et al
    Efficacy of fosfomycin in the prevention of postoperative infection following transurethral resection of bladder tumor during periods of limited cefazolin, cefotiam, and cefmetazole supply.
    J Infect Chemother. 2021;27:625-631.
    PubMed    
    Abstract available

  159. ORELLANA FM, Traete PL, de Toledo LGM
    Voiding dysfunction due to female urethral carcinoma.
    Int Urogynecol J. 2021;32:219-222.
    PubMed    


  160. OKUBO K, Isono M, Asano T, REssING N, et al
    Ubiquitin-proteasome System Is a Promising Target for Killing Cisplatin-resistant Bladder Cancer Cells.
    Anticancer Res. 2021;41:2901-2912.
    PubMed    
    Abstract available

  161. LOTAN Y
    Metabolic syndrome and bladder cancer.
    BJU Int. 2021;128:1-2.
    PubMed    


  162. DIRIE J, Mahesan T, Hart E, Janardanan S, et al
    Delivering safe and timely cancer care during COVID-19: lessons and successes from the transition period.
    BJU Int. 2021;127:633-635.
    PubMed    


  163. DAMRAUER JS, Roell KR, Smith MA, Sun X, et al
    Identification of a novel inflamed tumor microenvironment signature as a predictive biomarker of bacillus Calmette-Guerin immunotherapy in non-muscle invasive bladder cancer.
    Clin Cancer Res. 2021 Jun 11. pii: 1078-0432.CCR-21-0205.
    PubMed    
    Abstract available

  164. PEDERZOLI F, Bandini M, Raggi D, Marandino L, et al
    Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00387.
    PubMed    
    Abstract available

  165. HUSSAIN SA, Porta N, Hall E, Qureshi M, et al
    Reply to Santhanam Sundar and Paul Symonds' Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00347.
    PubMed    


  166. ZHANG R, Zang J, Xie F, Zhang Y, et al
    Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
    J Urol. 2021 Jun 1:101097JU0000000000001878. doi: 10.1097/JU.0000000000001878.
    PubMed    
    Abstract available

  167. CHAPPIDI MR, Welty C, Choi W, Meng MV, et al
    Evaluation of the Cancer of Bladder Risk Assessment (COBRA) Score in the Cancer Genome Atlas (TCGA) Bladder Cancer Cohort.
    Urology. 2021 Jun 9. pii: S0090-4295(21)00473.
    PubMed    
    Abstract available

  168. WANG Z, Tu L, Chen M, Tong S, et al
    Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    BMC Cancer. 2021;21:692.
    PubMed    
    Abstract available

  169. RIPOLL J, Ramos M, Montano J, Pons J, et al
    Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival.
    BMC Cancer. 2021;21:676.
    PubMed    
    Abstract available

  170. LYU X, Wang P, Qiao Q, Jiang Y, et al
    Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    BMC Cancer. 2021;21:646.
    PubMed    
    Abstract available

  171. CHEN X, Lin X, Pang G, Deng J, et al
    Significance of KDM6A mutation in bladder cancer immune escape.
    BMC Cancer. 2021;21:635.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;